5-Arylaminouracil Derivatives as Potential Dual-Action Agents

E S Matyugina; M S Novikov; D A Babkov; V T Valuev-Elliston; C Vanpouille; S Zicari; A Corona; E Tramontano; L B Margolis; A L Khandazhinskaya; S N Kochetkov

5-Arylaminouracil Derivatives as Potential Dual-Action Agents

Acta Naturae. 2015 Jul-Sep;7(3):113-5.

Authors

Affiliations

¹ Engelhardt Institute of Molecular Biology, Vavilova Str., 32, Moscow, 119991, Russia.
² Department of Pharmaceutical & Toxicological Chemistry, Volgograd State Medical University, Pavshikh Bortsov Sq., 1, Volgograd, 400131, Russia.
³ Eunice Kennedy-Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892, USA.
⁴ Department of Life and Environmental Sciences, University of Cagliari, Monserrato, 09042, Italy.

PMID: 26483967
PMCID: PMC4610172

Abstract

Several 5-aminouracil derivatives that have previously been shown to inhibit Mycobacterium tuberculosis growth at concentrations of 5-40 μg/mL are demonstrated to act also as noncompetitive non-nucleoside inhibitors of HIV-1 reverse transcriptase without causing toxicity in vitro (MT-4 cells) and ex vivo (human tonsillar tissue).

Keywords: 5-(phenylamino)uracil derivatives; 5’-norcarbocyclic nucleoside analogs; HIV and Mycobacterium tuberculosis co-infection; dual action.